Covaxin SRP

## Policy Analysis Report: COVAXIN SmPC Update Regarding Guillain-Barré Syndrome (GBS) **1. Executive Summary:** This report analyzes a communication from the Central Drugs Standard Control Organization (CDSCO), a division of the Directorate General of Health Services, Government of India, to Bharat Biotech International Limited. This communication mandates an update to the Summary of Product Characteristics (SmPC) – prescribing information – for the COVAXIN vaccine. The key change involves the inclusion of Guillain-Barré Syndrome (GBS) as a rare adverse event with unknown frequency following vaccination. The purpose is to ensure accurate and up-to-date information is available to healthcare professionals and patients regarding potential risks associated with COVAXIN. This is an amendment to the existing COVAXIN prescribing information. **2. Introduction:** This report provides an analysis of a communication (SRP COVAKIV F. No. X110261 12023BD) from the CDSCO to Bharat Biotech International Limited regarding the COVAXIN vaccine. The report focuses on the directive to update the SmPC for COVAXIN based on recommendations from the Signal Review Panel (SRP). The analysis is based solely on the content of the provided text. **3. Policy Overview:** * This communication serves as an amendment to the existing SmPC for COVAXIN (Whole Virion, Inactivated Coronavirus SARSCoV2 Vaccine). * **Core Objective(s):** Based on the text, the primary objective is to update the SmPC of COVAXIN to reflect the SRP's recommendation to include GBS as a rare adverse event. This ensures healthcare providers are informed of this potential risk, allowing for better patient management and informed consent. **4. Background and Rationale:** This communication acts as an amendment. The likely reason for this amendment is the Signal Review Panel's (SRP) assessment of AEFI (Adverse Event Following Immunization) related data and published medical literature. The SRP identified a potential safety signal related to COVAXIN and GBS. Including this information in the SmPC ensures healthcare professionals are aware of this potential risk and can monitor patients accordingly. **5. Key Provisions / Changes:** This communication acts as an amendment. The core change introduced is the directive to include the following statement in Section '4.8 Undesirable effects' of the COVAXIN SmPC: * "Unknown frequency: GuillainBarr Syndrome GBS following vaccination with COVAXIN" * **Specific Part of Original Policy Being Changed:** Section '4.8 Undesirable effects' of the existing COVAXIN SmPC. * **New Rule/Provision:** The inclusion of "Unknown frequency: GuillainBarr Syndrome GBS following vaccination with COVAXIN" within the SmPC. * **Difference/Effect of the Change:** This amendment ensures healthcare providers and patients are informed about the potential, albeit rare, risk of GBS following COVAXIN vaccination. This allows for improved risk-benefit assessment by clinicians and more informed decision-making by patients regarding vaccination. **6. Target Audience and Stakeholders:** Based on the text, the primary target audience is Bharat Biotech International Limited, as they are directly instructed to update the SmPC. Other stakeholders include: * Healthcare professionals prescribing and administering COVAXIN. * Patients receiving the COVAXIN vaccine. * The CDSCO, which oversees drug regulation and safety. * MoHEW (Ministry of Health and Family Welfare), under whose Immunization Division the SRP functions. **7. Implementation Aspects (Inferred):** * **Responsible Agency/Bodies:** * Bharat Biotech International Limited is responsible for updating the SmPC. * The CDSCO, specifically the Drugs Controller General India (Dr. V. G. Soman), oversees and approves the updated SmPC. * The Signal Review Panel (SRP) provides recommendations based on AEFI data evaluation. * **Timelines/Procedures:** The text requires Bharat Biotech to update the SmPC as per the SRP recommendations and submit the revised SmPC to the Directorate (CDSCO). Specific timelines for completion are not provided in the text. * The amendment requires Bharat Biotech to integrate the GBS information into the specific section of the SmPC, indicating a directed and controlled implementation. **8. Expected Outcomes / Impact of Changes:** The intended outcome of this amendment is to enhance transparency and provide healthcare professionals with the most up-to-date information regarding the safety profile of COVAXIN. The inclusion of GBS as a rare adverse event allows for: * Improved informed consent processes for patients. * Enhanced vigilance for GBS symptoms following vaccination. * Better risk-benefit assessment by healthcare providers. * Ultimately, contribute to better management of potential adverse events and greater public trust in vaccination programs. **9. Conclusion:** The communication from CDSCO to Bharat Biotech mandates a crucial update to the COVAXIN SmPC, specifically the inclusion of GBS as a rare adverse event. This amendment reflects an ongoing commitment to monitoring vaccine safety and providing healthcare professionals with the most accurate information available. This update is significant as it enhances transparency and allows for more informed decision-making regarding the use of COVAXIN.

Key Entities Referenced